

Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

EGFR +

Failed EFGR TKI

TKI
1st/3rd
Generation

EGFR 19
or 21

RET+

ALK +

KRAS G12
C+

MET/RET/ROS1

PTK7 + Study
Screening

LUN0123
Phase I/II
Selective RET
Inhibitor
TAS0953/HM06
in Advanced
Solid Tumors
w/ RET Gene
Abnormalities

PI: Wakelee
Pending

LUN0110
(Expanded
Access)
Expanded
Access
Intermediate-
Size Patient
Population
Protocol

PI: Wakelee
Xcovery

**ECOG
ACRIN-S1900-E**
Phase II AMG
510 in
Previously Tx
Stage IV or
Recurrent
KRAS G12C
Mutated
Non-Squamous
NSCLC LUNGMAP

PI: Neal
ECOG-ACRIN

**ECOG
ACRIN-EA5191**
Phase II
Cabozantinib
+/- Nivolumab
vs Standard
Chemotherapy
in Previously
Treated
Non-Squamous
NSCLC

PI: Neal
ECOG-ACRIN

LUN0111
Phase 1b
Cofetuzumab
Pelidotin
(ABBV-647)
in
PTK7-Expressing
Recurrent
NSCLC

PI: Neal
Pending

LUN0090
Phase I
Afatinib &
Necitumumab
in EGFR
Mutation+
NSCLC w/ 1st
/ 3rd Gen
EGFR TKIs
Acquired
Resistance

PI: Padda
Vanderbilt
University

LUN0112
Phase II
Carboplatin +
Pemetrexed
+
Bevacizumab
+/-
Atezolizumab
in Stage IV
Non-
Squamous
NSCLC

PI: Wakelee
NCTN

LUN0122
Phase I/II
JNJ-73841937
(Lazertinib)
Monotherapy
or in Combo w/
JNJ-61186372
in Advanced
NSCLC


PI: Neal
Janssen Research


THOR0006
Phase I/II
Nivolumab in
Combination
with Vorolanib
in Refractory
Thoracic
Tumors

PI: Wakelee
NCCN

KEY

 Pending

 Open for Enrollment

 Observational Study

 Optional Path

 Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy